Company Overview

Sagene Pharmaceuticals is a biopharmaceutical company developing novel applications for combinations of FDA-approved drugs to treat diseases associated with aging. Sagene has shown that selective MAO-B inhibitors, specifically selegiline (l-deprenyl), can reduce side effects and enhance efficacy in combination with current treatments for erectile dysfunction (ED), pulmonary arterial hypertension (PAH), pain/inflammation and cardiovascular diseases by targeting multiple disease pathways not typically addressed by currently approved drugs. These novel actions of selegiline have been patented by Sagene.

The combination approach for treating diseases with FDA-approved drugs to improve their therapeutic effect, reduces development risk, time and costs by utilizing the 505(b)(2) NDA approval process. Sagene has conducted preclinical studies showing proof of concept and the benefits of selegiline in laboratory animals and human platelets. Sagene’s intellectual property includes several patents to develop and produce drugs in combination with MAO-B inhibitors to treat erectile dysfunction (ED), pulmonary arterial hypertension (PAH), pain/inflammation and cardiovascular diseases.

Sagene was formed in 2010 to commercialize patented vascular disease discoveries initiated by founder Dr. Tom Thomas in 2001. Sagene’sManagement Team andScientific Advisors have significant experience with the FDA and drug development. Five members of the Sagene team are selegiline experts and played a major role in the clinical development and NDA preparation for the 2006 FDA approval of the selegiline (EMSAM®) patch for the treatment of Major Depressive Disorder (MDD) at Somerset Pharmaceuticals, which was acquired by Mylan Inc. in 2008.